Ever Green Stocks: Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), The AES Corporation (NYSE:AES), Wynn Resorts Ltd. (NASDAQ:WYNN), Pioneer Energy Services (NYSE:PES), NovaBay Pharmaceuticals (NYSEMKT:NBY)

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), announced new data from the ongoing Phase 1 dose escalation study of AG-221 as a single agent in patients with IDH2-mutant positive advanced hematologic malignancies. Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) belongs to Healthcare sector. Its net profit margin is -82.60% and weekly performance is 11.46%. On last trading day company shares ended up $107.30. Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) distance from 50-day simple … Continue reading Ever Green Stocks: Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), The AES Corporation (NYSE:AES), Wynn Resorts Ltd. (NASDAQ:WYNN), Pioneer Energy Services (NYSE:PES), NovaBay Pharmaceuticals (NYSEMKT:NBY)

Biotech Stocks: Ultragenyx Pharmaceutical Inc (NASDAQ:RARE), Prosensa Holding NV (NASDAQ:RNA), Agios Pharmaceuticals Inc (NASDAQ:AGIO), Seattle Genetics, Inc. (NASDAQ:SGEN), Idera Pharmaceuticals Inc (NASDAQ:IDRA)

Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) on July 9 announced the pricing of its underwritten public offering of 2,017,349 shares of its common stock at a price to the public of $40.00 per share, before underwriting discounts. Ultragenyx is selling 1,311,277 shares of its common stock in this offering, and certain selling stockholders are selling 706,072 shares of common stock in this offering. Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) … Continue reading Biotech Stocks: Ultragenyx Pharmaceutical Inc (NASDAQ:RARE), Prosensa Holding NV (NASDAQ:RNA), Agios Pharmaceuticals Inc (NASDAQ:AGIO), Seattle Genetics, Inc. (NASDAQ:SGEN), Idera Pharmaceuticals Inc (NASDAQ:IDRA)

Biotech Insider Buying: Merrimack Pharmaceuticals (NASDAQ:MACK), Omeros (NASDAQ:OMER), Insys Therapeutics (NASDAQ:INSY), Agios Pharmaceuticals (NASDAQ:AGIO), BioTime (NYSEMKT:BTX)

Merrimack Pharmaceuticals Inc (NASDAQ:MACK) Director Gary L. Crocker bought 36,000 shares of the stock in a transaction dated Monday, June 23rd. The shares were purchased at an average price of $6.84 per share, with a total value of $246,240.00. Merrimack Pharmaceuticals Inc (NASDAQ:MACK) stock performance was 3.91% in last session and finished the day at $7.44. Traded volume was 1.38million shares in the last session … Continue reading Biotech Insider Buying: Merrimack Pharmaceuticals (NASDAQ:MACK), Omeros (NASDAQ:OMER), Insys Therapeutics (NASDAQ:INSY), Agios Pharmaceuticals (NASDAQ:AGIO), BioTime (NYSEMKT:BTX)

Small Cap Losers: Ligand Pharmaceuticals Incorporated (NASDAQ:LGND), Altisource Asset Management (NYSEMKT:AAMC), Oncomed Pharmaceuticals (NASDAQ:OMED), Agios Pharmaceuticals (NASDAQ:AGIO)

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced that data from a Phase 1 study of the selective estrogen receptor modulator (SERM) lasofoxifene were featured in a poster presentation today at ICE/ENDO 2014 in Chicago.  Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) stock performance was -5.92% in last session and finished the day at $62.35. Traded volume was 400.60K shares in the last session and the average volume of the … Continue reading Small Cap Losers: Ligand Pharmaceuticals Incorporated (NASDAQ:LGND), Altisource Asset Management (NYSEMKT:AAMC), Oncomed Pharmaceuticals (NASDAQ:OMED), Agios Pharmaceuticals (NASDAQ:AGIO)

Biotech Losers: PTC Therapeutics (NASDAQ:PTCT), Prosensa Holding (NASDAQ:RNA), Concert Pharmaceuticals Inc (NASDAQ:CNCE), Tetralogic Pharmaceuticals Corp (NASDAQ:TLOG), Agios Pharmaceuticals Inc (NASDAQ:AGIO)

One solution, developed by PTC Therapeutics Inc. (NASDAQ:PTCT), a US biotechnology company, is to intervene in the transcription process in which the DNA is converted first to messenger RNA and then into protein. PTC Therapeutics Inc. (NASDAQ:PTCT)’s experimental drug ataluren is designed to override the false stop signal by interacting with the ribosome – the tiny biological machine inside every cell that runs along messenger … Continue reading Biotech Losers: PTC Therapeutics (NASDAQ:PTCT), Prosensa Holding (NASDAQ:RNA), Concert Pharmaceuticals Inc (NASDAQ:CNCE), Tetralogic Pharmaceuticals Corp (NASDAQ:TLOG), Agios Pharmaceuticals Inc (NASDAQ:AGIO)